New Access Devices Create Gateway To Interventional Structural Heart Disease
This article was originally published in Start Up
Executive Summary
Now that transcatheter heart valves have been implanted in thousands of humans, it’s becoming clear where the problems lie. Vascular and bleeding complications, stroke and paravalvular leaks are the most troubling consequences. Most of the focus has been on improving the valves and the delivery systems, but now innovators are looking at the issue of access – the particular ways by which therapeutic devices enter the heart – and how it can be changed to improve outcomes. In this issue we profile Apica Cardiovascular, Entourage Medical and Inseal Medical.
You may also be interested in...
Manufacturers Support CMS’ New TAVR National Coverage Decision
CMS has completed its new national Medicare Coverage with Evidence Development policy for transcatheter aortic valve replacement. The final decision memo largely maintains the recommendations from the draft version released in March, including more flexible criteria for centers establishing TAVR programs, while emphasizing the importance of the interdisciplinary heart team for decision-making about valve replacement.
The Medical Device Industry Stays The Course In 2012
The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, provided the industry with some momentum.
Medical Device Start-Up News, August 2012
This month we profile CoolSpine and its catheter-based hypothermia device, Inseal Medical and its large-bore vascular closure device, and MitrAssist Medical, which is developing a valve-in-valve approach to treating mitral regurgitation.